Wave Life Sciences, Inc.: MAVERICK CAPITAL LTD amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Maverick Capital Ltd amended its Schedule 13G filing for Wave Life Sciences Inc., updating its beneficial ownership stake with the SEC under accession number 0001012975-26-001060. The filing, submitted under the 13G regime used by passive and institutional investors, revises Maverick's reported position in the genetic medicines developer. The amendment signals a change in the hedge fund's holdings, though the filing summary did not disclose the revised share count or percentage. Investors will watch for the full filing details to gauge whether Maverick increased or trimmed its stake, and whether other institutional holders follow suit.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Wave Life Sciences, Inc., MAVERICK CAPITAL LTD